Mega M&A deals up in first quarter

Mergers and acquisitions (M&As) in biopharma have rebounded with a $76.9 billion increase in total deal value seen from 2022 to 2023, according to GlobalData.

In the first quarter of 2024 alone, biopharma M&A reached a total deal value of $43.5 billion, with a 71% year-on-year (YoY) increase in mega deals that were valued at $1 billion or more compared to the first quarter of 2023.w

Alison Labya, business fundamentals analyst at GlobalData, said: “The recent upturn in biopharmaceutical M&A signals a return in dealmaking confidence, as big pharma companies also look to mitigate the challenges such as the Inflation Reduction Act and upcoming patent expirations.”